miR-29a attenuates cardiac hypertrophy through inhibition of PPARδ expression
| Autor: | Si Zhang, Shu-Feng Zhang, Ming-Hui Yang, Ying-Wu Mei, Zhongnan Yin, Li-Xiang Xue, Zhi-Feng Fu, Fei-Fei Dai, Hao Wang, Meng-Jiao Zhou, Ming-Xi Zang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Physiology Clinical Biochemistry Down-Regulation Receptors Cytoplasmic and Nuclear Cardiomegaly Pharmacology 03 medical and health sciences Mice 0302 clinical medicine microRNA Transcriptional regulation Medicine Animals Myocytes Cardiac Receptor Mice Inbred ICR business.industry Lipid metabolism Cell Biology Peroxisome medicine.disease MicroRNAs 030104 developmental biology Nuclear receptor Gene Expression Regulation 030220 oncology & carcinogenesis Heart failure Cardiac hypertrophy cardiovascular system business Atrial Natriuretic Factor |
| Zdroj: | Journal of cellular physiology. 234(8) |
| ISSN: | 1097-4652 |
| Popis: | Although cardiac hypertrophy is widely recognized as a risk factor that leads to cardiac dysfunction and, ultimately, heart failure, the complex mechanisms underlying cardiac hypertrophy remain incompletely characterized. The nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ) is involved in the regulation of cardiac lipid metabolism. Here, we describe a novel PPARδ-dependent molecular cascade involving microRNA-29a (miR-29a) and atrial natriuretic factor (ANF), which is reactivated in cardiac hypertrophy. In addition, we identify a novel role of miR-29a, in which it has a cardioprotective function in isoproterenol hydrochloride-induced cardiac hypertrophy by targeting PPARδ and downregulating ANF. Finally, we provide evidence that miR-29a reduces the isoproterenol hydrochloride-induced cardiac hypertrophy response, thereby underlining the potential clinical relevance of miR-29a in which it may serve as a potent therapeutic target for heart hypertrophy treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text